CP therapy (Carboplatin and Paclitaxel) for advansed malignant melanoma

CP therapy (Carboplatin and Paclitaxel) for advansed malignant melanoma - MMCP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004073

Enrollment

Registered

2010-09-01

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant melanoma

Interventions

CP(carboptatin

6AUC+paclitaxel

200mg/m2), monthly DAC-Tam (DTIC, ACNU, cisplatin Tamoxifen)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: advanced melanoma

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
overall survaival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026